

April 18, 2024

U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F. Street, N.E.
Washington, D.C. 20549
Attention: Filing Desk

Re: Enliven Therapeutics, Inc. Registration Statement on Form S-3

Ladies and Gentlemen:

On behalf of Enliven Therapeutics, Inc. (the “Company”), we submit for filing under the Securities Act of 1933, as amended (the “Securities Act”), a Registration Statement on Form S-3 (the “Registration Statement”) covering the resale of certain securities by the Selling Stockholders identified in the Registration Statement. We write to notify you that the Company does not intend to request the Registration Statement be made effective until such time as it has filed the definitive proxy statement for its 2024 annual meeting of stockholders, which will include and incorporate by reference into the Company’s Form 10-K for the fiscal year ended December 31, 2023, the information required by Part III of Form 10-K.

Please call me at (650) 849-3436 with any questions or comments.

Best regards,

WILSON SONSINI GOODRICH & ROSATI
Professional Corporation

/s/ Rachel J. Nagashima
Rachel J. Nagashima

AUSTIN BEIJING BOSTON BOULDER BRUSSELS HONG KONG LONDON LOS ANGELES NEW YORK PALO ALTO
SALT LAKE CITY SAN DIEGO SAN FRANCISCO SEATTLE SHANGHAI WASHINGTON, DC WILMINGTON, DE